Tonix Pharmaceuticals (TNXP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TNXP Tonix Pharmaceuticals

Watchlist

0.1897
+0.0014+0.74%

Close Nov 29 13:00 ET

0.1904
+0.0007+0.37%

Post 16:11 ET

35.45MMarket Cap-2P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tonix Pharma Talks NDA for Fibromyalgia Drug, FDA Decision on NDA Acceptance Expected December 2024 | NASDAQ:TNXP
Proactive InvestorsNov 27 10:54 ET
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Seeking AlphaNov 23 14:48 ET
Express News | World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
BenzingaNov 22 12:43 ET
Looking Into Tonix Pharmaceuticals's Recent Short Interest
BenzingaNov 22 12:00 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaNov 20 16:10 ET
Quantum-Si QSI SkyWater Deal Expansion; Tonix Pharmaceuticals TNXP Phase 3 Data
BioPharmCatalystNov 20 08:21 ET

Comments

Angelos

Nov 27 11:01

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Angelos

Nov 27 10:57

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Nov 27 10:23

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Nov 27 10:15

$Tonix Pharmaceuticals (TNXP.US)$ https://youtu.be/v_VIj3lMETU?si=mKwShpRtJb54IFS2

我要向钱看

Nov 27 10:05

CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...